325 results on '"A. Lambertini"'
Search Results
2. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
3. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe
4. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†
5. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
6. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting
7. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
8. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients
9. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies
10. 146P HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial)
11. 231P Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
12. 504P SARS-CoV-2 Omicron (B.1.1.529) variant infection leads to high morbidity and mortality in unvaccinated patients with cancer
13. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
14. 1558MO Dissecting sexual health after breast cancer (BC) by longitudinal assessment of patient reported outcomes
15. 1551O Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study
16. 1897P Time to access to diagnosis and treatment for lung cancer (LC): Experience within an Italian comprehensive cancer center
17. 1815O Breastfeeding after breast cancer in young BRCA carriers: Results from an international cohort study
18. 429P Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives
19. 357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)
20. 338TiP EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
21. 302P Perceptions of women with HER2+ breast cancer on the risk of recurrence and disease management: Results from the ASKHER survey
22. 290P Subtype-specific prognostic value of lobular histology in patients with early-stage breast cancer: A nationwide population-based study
23. 269P Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
24. 243P Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
25. 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial
26. 113P Axillary lymph node management in early breast cancer patients with positive sentinel lymph node: A systematic review and meta-analysis of randomized trials
27. 177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)
28. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
29. 1558MO Dissecting sexual health after breast cancer (BC) by longitudinal assessment of patient reported outcomes
30. 504P SARS-CoV-2 Omicron (B.1.1.529) variant infection leads to high morbidity and mortality in unvaccinated patients with cancer
31. 1206P HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) + trastuzumab (T) +/- pertuzumab (P) in the JACOB trial
32. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
33. C2* - A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer
34. C6 - The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
35. Reply to the letter to the editor ‘Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?’ by Rodriguez-Wallberg et al.
36. 1551O Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study
37. 231P Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
38. 146P HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial)
39. 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella
40. 131P Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer
41. 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes
42. 1687P Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomized controlled trials: A systematic review and meta-analysis
43. 1565MO Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry
44. 316P Attitudes towards the use of stereotactic body radiation therapy in oligometastatic breast cancer: Results of an OncoAlert survey
45. 202TiP ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy
46. 1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: A systematic review and meta-analysis
47. 128P Characteristics, patterns of care and outcomes of young women with breast cancer (BC) according to age, year of diagnosis and germline BRCA status (gBRCA)
48. 1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series
49. VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)
50. 113P Axillary lymph node management in early breast cancer patients with positive sentinel lymph node: A systematic review and meta-analysis of randomized trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.